| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg | |||
| Other Sizes |
Purity: ≥98%
| Targets |
The primary target of RH01687 is the pathways involved in endoplasmic reticulum (ER) stress-induced apoptosis in pancreatic β-cells. By protecting these cells from death, it aims to preserve β-cell function and insulin production.
|
|---|---|
| ln Vitro |
In vitro, RH01687 has demonstrated significant potential in protecting pancreatic β-cells from cell death caused by ER stress. The specific molecular readouts of its activity involve the reduction of ER stress markers and the prevention of apoptosis in β-cell lines.
|
| ln Vivo |
In vivo efficacy data for RH01687 is not detailed in the provided search results. However, its potential for diabetes research is highlighted, suggesting it may be tested in animal models of diabetes to assess its ability to preserve β-cell mass and improve glucose homeostasis.
|
| Enzyme Assay |
The assay for evaluating RH01687's activity typically involves culturing pancreatic β-cell lines, such as INS-1 or MIN6 cells, and inducing ER stress using agents like tunicamycin or thapsigargin. Cells are co-treated with RH01687, and cell viability is measured using assays like MTT or by quantifying apoptotic markers.
|
| Cell Assay |
Cellular experiments use β-cell lines in standard culture media. Cells are pre-treated with RH01687 before the addition of an ER stress inducer. The protective effect is quantified by assessing cell viability, caspase activity, or the expression of ER stress-related proteins (e.g., CHOP, BiP) via Western blot.
|
| Animal Protocol |
In vivo, the compound would likely be administered to rodent models of type 2 diabetes, such as db/db or high-fat diet-fed mice. The endpoint would be the measurement of β-cell mass, insulin secretion, and blood glucose levels to determine if RH01687 can prevent the progression of diabetes.
|
| ADME/Pharmacokinetics |
RH01687 has a molecular weight of 336.75 g/mol and a molecular formula of C12H9ClN6O2S. Specific pharmacokinetic parameters such as bioavailability and half-life are not available in the search results.
|
| Toxicity/Toxicokinetics |
Specific toxicity data for RH01687 is not available in the search results. As a research compound, its safety profile has not been fully established.
|
| Additional Infomation |
RH01687 is a research compound with potential applications in the study of diabetes. It is not approved for clinical use and is currently only available for preclinical research. Its mechanism of action is centered on the protection of pancreatic β-cells from ER stress-induced apoptosis.
|
| Molecular Formula |
C12H9CLN6O2S
|
|---|---|
| Molecular Weight |
336.754
|
| Exact Mass |
336.019
|
| Elemental Analysis |
C, 42.80; H, 2.69; Cl, 10.53; N, 24.96; O, 9.50; S, 9.52
|
| CAS # |
302901-13-9
|
| Related CAS # |
302901-13-9;
|
| PubChem CID |
3811346
|
| Appearance |
Solid powder
|
| Density |
1.8±0.1 g/cm3
|
| Boiling Point |
628.6±65.0 °C at 760 mmHg
|
| Flash Point |
334.0±34.3 °C
|
| Vapour Pressure |
0.0±1.8 mmHg at 25°C
|
| Index of Refraction |
1.821
|
| LogP |
3.51
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
22
|
| Complexity |
408
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
ClC1=CC(=C(C=C1N1C=CC=C1)SC1=NNC(N)=N1)[N+](=O)[O-]
|
| InChi Key |
BOVTVNWNYFQVMI-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C12H9ClN6O2S/c13-7-5-9(19(20)21)10(22-12-15-11(14)16-17-12)6-8(7)18-3-1-2-4-18/h1-6H,(H3,14,15,16,17) SMILES
|
| Chemical Name |
3-(4-Chloro-2-nitro-5-pyrrol-1-ylphenyl)sulfanyl-1H-1,2,4-triazol-5-amine
|
| Synonyms |
RH01687 RH-01687 RH 01687.
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~296.95 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.9696 mL | 14.8478 mL | 29.6956 mL | |
| 5 mM | 0.5939 mL | 2.9696 mL | 5.9391 mL | |
| 10 mM | 0.2970 mL | 1.4848 mL | 2.9696 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA